Unterehmen auf Watchlist setzen
Mineralys Therapeutics
ISIN: US6031701013
WKN: A3D5YN
Über
Unternehmensprofil
Tipp: Investor-Alerts aktivieren
Lassen Sie sich bei neuen Publikationen informieren
Tipp: AI-Factsheet

Corporate News meets AI! 
Analyse der Inhalte und Zusammenfassung

Mineralys Therapeutics · ISIN: US6031701013 · PR Newswire (ID: 20240911DC02002)
11 September 2024 10:00PM

MLYS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Mineralys Therapeutics, Inc. and Encourages Investors to Contact the Firm!


NEW YORK, Sept. 11, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ: MLYS). Investors who purchased Mineralys securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MLYS.

Investigation Details

On August 13, 2024, Mineralys released its second quarter 2024 financial results. The Company's earnings per share badly missed analyst consensus estimates. Following this news, Mineralys' stock dropped sharply that same day.

What's Next?

If you are aware of any facts relating to this investigation or purchased Mineralys securities, you can assist this investigation by visiting the firm's site: bgandg.com/MLYS. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Nathan Miller

332-239-2660 | info@bgandg.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/mlys-investor-alert-bronstein-gewirtz-and-grossman-llc-announces-an-investigation-into-mineralys-therapeutics-inc-and-encourages-investors-to-contact-the-firm-302244047.html

SOURCE Bronstein, Gewirtz & Grossman, LLC

Visuelle Wertentwicklung / Kursverlauf · Mineralys Therapeutics
Smarte Analyse- und Recherchewerkzeuge finden Sie hier.
This publication was provided by our content partner PR Newswire
PR Newswire
via PR Newswire - Newsfeed
Cision ©2025
PR Newswire
Kontakt:
300 S Riverside Plaza, Chicago, Illinois, USA
+001 (0) 888-776-0942